Clinical Trial Update: RFT-5-dgA in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for RFT-5-dgA in metastatic melanoma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RFT-5-dgA

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-11-12